ライフサイエンスコーパス: confidence interval

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 noninferiority was based on a 1-sided 97.5% confidence interval.

2 was used to estimate relative risks and 95% confidence intervals.

3 was used to calculate hazard ratios and 95% confidence intervals.

4 hildren in the control group (RR = 0.90 [95% confidence intervals 0.80-1.00]).

5 lower risks of BCC (hazard ratio = 0.6; 95% confidence interval = 0.4-0.9) but significantly higher

6 urgical complications (odd ratio = 0.71, 95% confidence interval = 0.60-0.83, P < 0.05) as compared w

7 ce interval [0.77, 0.88], vertical 0.76, 95% confidence interval [0.68, 0.82]).

8 correlation coefficient horizontal 0.83, 95% confidence interval [0.77, 0.88], vertical 0.76, 95% con

9 nfectious units per million cells (IUPM; 95% confidence interval, 0.26-0.55 IUPM), 3-fold lower than

10 nmatched population (hazard ratio, 0.57; 95% confidence interval, 0.33-0.98; P=0.04).

11 dification patients (hazard ratio, 0.54; 95% confidence interval, 0.36-0.82).

12 , adjunct vs. control; odds ratio, 0.89; 95% confidence interval, 0.46-1.74; P = 0.733).

13 79.5% in the POC arm (odds ratio, 1.13; 95% confidence interval, 0.51-2.53; P = 0.76; risk differenc

14 61-0.78) and sisters hazard ratios=0.65 (95% confidence interval, 0.52-0.80), respectively.

15 after LVAD (adjusted hazard ratio, 0.73; 95% confidence interval, 0.58-0.92; P=0.007).

16 hazard ratio for heart failure of 0.77 (95% confidence interval, 0.60-0.97) in both treatment groups

17 nce between brothers hazard ratios=0.69 (95% confidence interval, 0.61-0.78) and sisters hazard ratio

18 myocardial infarction (odds ratio, 0.76; 95% confidence interval, 0.61-0.94; P=0.01) compared with CA

19 thout any masked hypertension was 0.681 (95% confidence interval, 0.640-0.723) for ASCVD risk and 0.7

20 , 0.640-0.723) for ASCVD risk and 0.703 (95% confidence interval, 0.663-0.744) for clinic systolic BP

21 omized to PCI alone (hazard ratio, 0.84; 95% confidence interval, 0.70-1.01; P=0.06).

22 een the PSF and the PSFEARL DS was 0.82 (95% confidence interval, 0.73-0.91) for i-PET and 0.89 (95%

23 a survival benefit (hazard ratio, 0.82; 95% confidence interval, 0.75-0.90; P<0.001).

24 the glargine group (hazard ratio, 0.91; 95% confidence interval, 0.78 to 1.06; P<0.001 for noninferi

25 interval, 0.73-0.91) for i-PET and 0.89 (95% confidence interval, 0.81-0.96) for EoT-PET.

26 0.46) or amlodipine (hazard ratio, 0.93; 95% confidence interval, 0.84-1.03; P=0.16) was not associat

27 6-1.24; P=0.001, and hazard ratio, 0.99; 95% confidence interval, 0.92-1.07; P=0.81, respectively; P

28 o either lisinopril (hazard ratio, 1.04; 95% confidence interval, 0.94-1.15; P=0.46) or amlodipine (h

29 rd ICD RPM patients (hazard ratio, 1.06; 95% confidence interval, 0.94-1.19; P=0.34).

30 sychosocial factors (hazard ratio, 1.14; 95% confidence interval, 0.96-1.35), the association was att

31 riminate CA (area under the curve, 0.95; 95% confidence intervals, 0.89-0.98; P<0.00005).

32 s (standardized mean difference = -0.32 [95% confidence interval, -0.44 to -0.19]).

33 MS patients (12.0%) (hazard ratio: 0.54; 95% confidence interval: 0.41 to 0.72; p < 0.0001).

34 uction in odds of CAD (odds ratio: 0.66; 95% confidence interval: 0.44 to 0.98; p = 0.04).

35 .84-1.37) and VNTR 7 DRD4 (odds ratio: 0.68; confidence interval: 0.47-1.00).

36 ated with better OS (hazard ratio 0.569, 95% confidence interval: 0.478-0.677, P < 0.001) independent

37 -2.37) and VNTR 10 SLC6A3 (odds ratio: 0.74; confidence interval: 0.60-0.90), whereas the following v

38 nificant: rs1947274 LPHN3 (odds ratio: 0.95; confidence interval: 0.71-1.26), rs5661665 LPHN3 (odds r

39 was reduced by 13% (hazard ratio = 0.87, 95% confidence interval: 0.79, 0.96).

40 ated with a decrement of 3.70 IQ points (95% confidence interval: 0.83, 6.56).

41 71-1.26), rs5661665 LPHN3 (odds ratio: 1.07; confidence interval: 0.84-1.37) and VNTR 7 DRD4 (odds ra

42 poverty at age 7-14 years (beta = -0.01, 95% confidence interval: -0.04, 0.01) and school attendance/

43 ars (i.e., joint mediators beta = -0.07, 95% confidence interval: -0.12, -0.02) than the indirect eff

44 indicators; n = 5,292; 30%) had a 2.2% (95% confidence interval: -0.3% to 4.6%) absolute risk reduct

45 nd apolipoprotein B (change in SD units [95% confidence interval]: -0.98 [-1.11, -0.86]) with similar

46 t risk of FMT failure (odds ratio, 0.15; 95% confidence interval, .007-.40).

47 for women undergoing CPM (BCSS: HR 1.08, 95% confidence interval 1.01-1.16; OS: HR 1.08, 95% confiden

48 fidence interval 1.01-1.16; OS: HR 1.08, 95% confidence interval 1.03-1.14), regardless of HR status

49 the resection group (relative risk 3.01, 95% confidence interval 1.15-7.90).

50 ivariate analysis (hazard ratio = 1.694, 95% confidence interval 1.175-2.442).

51 ted to neovascular AMD (odds ratio 1.55 [95% confidence interval 1.31-1.84], P = 2.67 x 10(-7)).

52 adjusted hazard ratios 0-14 years: 1.51 [95% confidence intervals 1.19 to 1.90]; 15-24 years: 1.37 [1

53 l monthly mean (prevalence ratio = 1.31 [95% confidence interval = 1.05-1.63] per kJ/m(2)) and minimu

54 est statistic [df] = 6.58 [1], P = 0.01; 95% confidence interval = 1.06 to 1.55).

55 higher risks of SCC (hazard ratio = 2.3; 95% confidence interval = 1.5-3.6).

56 d retrieval technique (odds ratio, 1.08; 95% confidence interval, 1.05-1.10; P<0.001).

57 en but not in women (hazard ratio, 1.14; 95% confidence interval, 1.06-1.24; P=0.001, and hazard rati

58 utional volume of BAV (odds ratio, 1.58; 95% confidence interval, 1.06-2.37; P=0.03).

59 mortality (P = 0.003; odds ratio, 1.254; 95% confidence interval, 1.078-1.457).

60 fect was attenuated (hazard ratio, 1.16; 95% confidence interval, 1.08-1.25; P<0.001).

61 asthma at baseline (hazard ratio, 1.51; 95% confidence interval, 1.08-2.10) after adjusting for conf

62 per year (odds ratio for increase, 1.17; 95% confidence interval, 1.09-1.27) from fiscal year 2000 th

63 s <limit of detection; odds ratio, 1.50; 95% confidence interval, 1.09-2.07), but not with decline in

64 al outcome (adjusted relative risk, 1.6; 95% confidence interval, 1.1-2.5; P=0.02).

65 eyond traditional risk (odds ratio, 6.0; 95% confidence interval, 1.1-31.7; P=0.03).

66 y associated with STDR (odds ratio, 2.3; 95% confidence interval, 1.1-4.9; P = 0.04).

67 istory of sudden death (odds ratio, 3.2; 95% confidence interval, 1.1-9.4) were independently associa

68 confounding factors (hazard ratio, 1.69; 95% confidence interval, 1.10-2.61; P = 0.018).

69 for fourth versus first quartile, 1.81; 95% confidence interval, 1.11 to 2.96; Ptrend=0.04).

70 talization (adjusted hazard ratio, 1.34; 95% confidence interval, 1.11-1.60; P=0.002) and death (haza

71 isk of graft failure 3.59 times as high (95% confidence interval, 1.12 to 15.94) as that of patients

72 of transfer patients (odds ratio, 1.47; 95% confidence interval, 1.13-1.92; P=0.005).

73 HIV was associated with LBW (aRR = 1.74; 95% confidence interval, 1.18, 2.58; P < .01).

74 h survival (adjusted relative risk, 1.7; 95% confidence interval, 1.2-2.6; P=0.007) and survival with

75 d hazard ratio for publication was 1.79 (95% confidence interval, 1.20-2.67) in favor of licensed dru

76 In 3% of cases (95% confidence interval, 1.3%-6.7%), there was clinically me

77 event-40% higher than expected (SHR=1.4, 95% confidence interval, 1.3-1.4).

78 ted annual incidence of 1.8 per 100 000 (95% confidence interval, 1.3-2.2) between 1990 and 2014.

79 ular death (adjusted hazard ratio, 2.16; 95% confidence interval, 1.36-3.43; P=0.001).

80 increased odds of cardioembolic stroke (95% confidence interval, 1.39-4.58; P=2.7x10(-3)).

81 s both in allo-HSCT (hazard ratio, 2.13; 95% confidence interval, 1.45-3.13; P <.001) and auto-HSCT (

82 quent MACE (adjusted hazard ratio, 1.90; 95% confidence interval, 1.46-2.48; P<0.001), all-cause deat

83 <0.001), coagulopathy (odds ratio, 2.19; 95% confidence interval, 1.51-3.18; P<0.001), and low instit

84 omy (vs duct-to-duct) (odds ratio, 3.06; 95% confidence interval, 1.52-6.16; P = 0.002).

85 x 10(5) particles/ml higher carbon load (95% confidence interval, 1.56 x 10(5) to 9.10 x 10(5) partic

86 omparing blacks versus whites were 2.61 (95% confidence interval, 1.57-4.34) and 1.79 (1.06-3.03), re

87 Prior syncope (odds ratio, 4.0; 95% confidence interval, 1.6-9.7) and a family history of su

88 P=0.002) and death (hazard ratio, 2.10; 95% confidence interval, 1.60-2.75; P<0.001) increased in th

89 cific death (adjusted hazard ratio, 2.3; 95% confidence interval, 1.7-3.0; P < 0.001).

90 variable) showed a hazard ratio of 2.25 (95% confidence interval, 1.70-2.99) after adjusting for othe

91 l, 4.7-55.9) and COPD (odds ratio, 5.76; 95% confidence interval, 1.9-17.4), but not asthma alone.

92 recurrent stroke/TIA (hazard ratio, 2.0; 95% confidence interval, 1.9-2.1).

93 rdiovascular causes (hazard ratio, 2.32; 95% confidence interval, 1.92-2.81 versus type 1 myocardial

94 (odds ratio per 5-mbar increase = 1.06, 95% confidence interval: 1.01, 1.11), which could not be dis

95 y-stable DII group (hazard ratio = 1.32, 95% confidence interval: 1.01, 1.74).

96 igher risk of anemia (odds ratio = 1.14; 95% confidence interval: 1.01-1.28) and a lower hemoglobin c

97 mprovements (incidence rate ratio, 1.04; 95% confidence interval: 1.02, 1.07) (P = .002).

98 .17), and for low frequency/HF was 1.08 (95% confidence interval: 1.03 to 1.14).

99 ivariable-adjusted relative risk = 1.09, 95% confidence interval: 1.04, 1.14; P for trend < 0.001) we

100 2-2.55), rs4680 COMT (odds ratio (OR): 1.40; confidence interval: 1.04-1.87), rs5569 SLC6A2 (odds rat

101 nterval: 1.08 to 1.21), for HF was 1.12 (95% confidence interval: 1.06 to 1.17), and for low frequenc

102 .33) and MELD score (hazard ratio, 1.08; 95% confidence interval: 1.06, 1.11) were found to be indepe

103 ivariable-adjusted relative risk = 1.10, 95% confidence interval: 1.06, 1.15; P for trend < 0.001) an

104 normal-to-normal RR intervals was 1.14 (95% confidence interval: 1.08 to 1.21), for HF was 1.12 (95%

105 ng risks, LSN score (hazard ratio, 1.22; 95% confidence interval: 1.11, 1.33) and MELD score (hazard

106 s (SNPs) rs1800544 ADRA2A (odds ratio: 1.69; confidence interval: 1.12-2.55), rs4680 COMT (odds ratio

107 ndem repeat (VNTR) 4 DRD4 (odds ratio: 1.66; confidence interval: 1.16-2.37) and VNTR 10 SLC6A3 (odds

108 the combined endpoint (odds ratio: 2.73; 95% confidence interval: 1.2 to 5.9; p = 0.01).

109 diovascular disease (hazard ratio = 1.4, 95% confidence interval: 1.2, 1.6), compared with men with a

110 1.04-1.87), rs5569 SLC6A2 (odds ratio: 1.73; confidence interval: 1.26-2.37) and rs28386840 SLC6A2 (o

111 se hospitalizations (hazard ratio = 1.5, 95% confidence interval: 1.4, 1.6) and cardiovascular diseas

112 37) and rs28386840 SLC6A2 (odds ratio: 2.93; confidence interval: 1.76-4.90), and, repeat variants va

113 r hemoglobin concentration of -0.84 g/L (95% confidence interval: -1.33 to -0.35) in children aged 4-

114 protein cholesterol (change in SD units [95% confidence interval]: -1.01 [-1.14, -0.88]), remnant cho

115 remnant cholesterol (change in SD units [95% confidence interval]: -1.03 [-1.17, -0.89]), and apolipo

116 onfidence interval, 42% to 67%] and 14% [95% confidence interval, 11% to 18%] higher hospitalization

117 gest predictor of OD (odds ratio = 14.8; 95% confidence interval: 12.7-17.2).

118 447 HU +/- 166, respectively [P = .241]; 95% confidence interval: -15.1, 60.0), including those from

119 1-2.53; P = 0.76; risk difference, 3.1%; 95% confidence interval, -16.2 to 10.1).

120 (14 deaths; incidence rate ratio, 0.31 [95% confidence interval, .16-.61]; P = .0003), when most dea

121 by positive serum HBsAg, of 2.9% (upper 95% confidence interval, 19%).

122 of developing AF was 21.99 times higher (95% confidence interval, 19.26-25.12) in patients with CHD t

123 ause death (adjusted hazard ratio, 2.96; 95% confidence interval, 2.01-4.36; P<0.001), and cardiovasc

124 d >7 beats (adjusted hazard ratio, 6.26; 95% confidence interval, 2.02-19.41; P=0.0015).

125 r the primary composite outcome of 3.52 (95% confidence interval, 2.17 to 5.71).

126 ricular assist device (odds ratio, 3.48; 95% confidence interval, 2.25-5.36; P<0.001), coagulopathy (

127 receiving preferred beta-lactam therapy (95% confidence interval, 2.4-8.2; P < .0001).

128 rical comparison group (odds ratio: 4.0; 95% confidence interval: 2.08 to 7.7; p < 0.0001).

129 (adjusted relative median dose, 2.6 mGy [95% confidence interval: 2.5, 2.7]).

130 oquinolone (adjusted hazard ratio, 0.46 [95% confidence interval, .26-.80]) during follow-up.

131 ter contribution to xylem water) is 37% (95% confidence interval, 28-46%).

132 ian cancer-related survival was 37.7 months (confidence interval 29-46 mo).

133 ment was associated with VF (SHR, 11.50 [95% confidence interval, 3.92-33.74]; P < .001).

134 nt-free survival was estimated at 49.0% (95% confidence interval, 33.3%-62.9%) in the former and 52.4

135 e in 444 failure occurred in 187 (42.1%; 95% confidence interval, 37.5%-46.7%) after a median of 62 d

136 er minute (adjusted hazard ratio, 15.63; 95% confidence interval, 4.01-60.89; P<0.0001) and >7 beats

137 ere cardiogenic shock (odds ratio, 6.01; 95% confidence interval, 4.19-8.61; P<0.001), need for left

138 associated with ACOS (odds ratio, 16.3; 95% confidence interval, 4.7-55.9) and COPD (odds ratio, 5.7

139 ly worse for the OAC alone group: 67.1% (95% confidence interval, 40.9%-83.6%) versus 94.1% (95% conf

140 ged 18-34 years and >/=75 years had 54% [95% confidence interval, 42% to 67%] and 14% [95% confidence

141 fter a single ablation procedure of 54% (95% confidence interval, 43%-68%) in the PVI-only and 57% (9

142 erval, 43%-68%) in the PVI-only and 57% (95% confidence interval, 46%-72%) in the Substrate-modificat

143 ian overall survival (OS) was 30 months (95% confidence interval, 6-54) from start of midostaurin.

144 24-6.57) than nonrotor domains (6.17 Hz; 95% confidence interval, 6.1-6.23; P=0.021), with interatria

145 higher frequency of activation (6.41 Hz; 95% confidence interval, 6.24-6.57) than nonrotor domains (6

146 nce interval, 40.9%-83.6%) versus 94.1% (95% confidence interval, 65%-99.1%) for the OAC plus intravi

147 s discovered at prophylactic mastectomy (95% confidence interval: 69.5%, 82.4%) and 90.0% excluding t

148 nfidence interval, 89.2-99.4) and 86.2% (95% confidence interval, 78.7-94.5), respectively.

149 2.4%) and 90.0% excluding those cancers (95% confidence interval: 83.3%, 93.7%).

150 ed 4-year event-free survival was 89.7% (95% confidence interval 84.1-95.2%) and overall survival was

151 al and disease-free survival were 94.2% (95% confidence interval, 89.2-99.4) and 86.2% (95% confidenc

152 was achieved by 98% of patients (51/52; 95% confidence interval, 90%-100%).

153 he highest accuracy (97%, 34 of 35 eyes, 95% confidence interval 92%-100%) for classifying an eye as

154 nce (SMD) of thyroid hormone levels with 95% confidence intervals (95% CI) obtained from the studies

155 Multivariable hazard ratios (HRs) and 95% confidence intervals (95%CI) for developing colorectal c

156 r creatinine, we found y = 0.73x - 1.55 (95% confidence interval [95% CI] slope, 0.71-0.76), giving t

157 quartile hazard ratio for DDKF was 2.47 (95% confidence interval [95% CI], 1.21-5.05).

158 ing SMR over time [odds ratio (OR) 1.73; 95% confidence interval (CI) 1.03-2.91; P = 0.03].

159 city versus non-Hispanic White (OR 1.10, 95% confidence interval (CI) 1.05-1.16), and care at a Natio

160 d with 30-day POM [odds ratio (OR) 1.71; 95% confidence interval (CI) 1.05-2.77); P = 0.032], whereas

161 [(+)transfusion: hazard ratio (HR) 1.19, 95% confidence interval (CI) 1.09-1.30; (+)sepsis: HR 1.84,

162 lation [incidence rate ratio (IRR) 1.47, 95% confidence interval (CI) 1.11-1.94, P = 0.005].

163 sed risk of basal-like subtype [OR 4.17; 95% confidence interval (CI) 1.89-9.21] compared with both n

164 ere opioid-naive) had 9.2% higher costs [95% confidence interval (CI) 2.8%-15.6%; adjusted means $26,

165 ancer [adjusted odds ratios (OR) = 3.90, 95% confidence interval (CI) = 2.65-5.73].

166 eriority required the lower limit of the 95% confidence interval (CI) of the differences in CRs not e

167 TKR for subjects with diabetes was 0.63 [95% confidence interval (CI), 0.52-0.75] after controlling f

168 resence by 1.5-fold (odds ratio [OR] = 1.56 [confidence interval (CI), 1.22-2.00]; P < 0.001) and 2-f

169 nalysis to estimate risk ratio (RR) with 95% confidence interval (CI).

170 was reported in hazard ratios (HR) with 95% confidence interval (CI).

171 odds ratios (ORs) or beta-estimates with 95% confidence interval (CI).

172 hildren was large in the NCDS [-0.37 SD, 95% confidence interval (CI): -0.46, -0.27] and in the BCS (

173 loped new vessels, odds ratio (OR) 0.12 [95% confidence interval (CI): 0.01, 1.03].

174 s. lowest (1st), odds ratio (OR) = 0.66, 95% confidence interval (CI): 0.45, 0.98; P for trend = 0.05

175 second quintile hazard ratio (HR)=1.03 [95% confidence interval (CI): 0.86, 1.25]; third quintile HR

176 able-adjusted relative risk (RR) = 0.99, 95% confidence interval (CI): 0.90, 1.09), skin tanning abil

177 ) for ER visits for GI illness was 1.09 [95% confidence interval (CI): 1.03, 1.16] in the 10-14 d per

178 h AF (adjusted hazard ratio (HR) = 1.19, 95% confidence interval (CI): 1.03, 1.38).

179 tumors (pooled odds ratio (pOR) = 1.32, 95% confidence interval (CI): 1.10, 1.58).

180 usted incidence rate ratio (IRR) = 1.86, 95% confidence interval (CI): 1.27, 2.71; for infected wound

181 uccessful agers (N = 789) reported 3.79 (95% confidence interval (CI): 1.39-6.19) minutes more daily

182 onal pathway, GMs were 2.3 times higher [95% confidence interval (CI): 1.5, 3.3; 15 statistics, five

183 first quartile, odds ratio (OR) = 2.70, 95% confidence interval (CI): 1.55, 4.70) and current smoker

184 t the infection attack rates were 78.0% (95% confidence interval (CI): 63.5-86.3%) in French Polynesi

185 e cancer registries (sensitivity of 89%, 95% confidence interval (CI): 86, 92).

186 ious infection; the incidence rates with 95% confidence intervals (CI) per 1,000 person-years were as

187 ecurrences and hazard ratios (HRs), with 95% confidence intervals (CI), for the time-dependent risk r

188 0.24 to 0.10 (adjusted risk ratio 0.44, 95% confidence interval [CI] 0.26-0.75).

189 pared to AA adults (odds ratio [OR] 0.50 95% confidence interval [CI] 0.31-0.79, P = 0.003), schoolch

190 difference of 15.8 percentage points; 97.5% confidence interval [CI] 0.5-31.2; P = .021).

191 al safety climate (Odds Ratio [OR]=2.76, 95% Confidence Interval [CI] 1.51-5.03), people-oriented cul

192 h vivax malaria within 1 year was 33.8% (95% confidence Interval [CI] 33.1%-34.5%) after initial mono

193 ase in the CT (32% decrease in DTN time, 95% confidence interval [CI] 38%-55%), stretcher to CT (30%

194 Overall SVR rates were 89.8% (95% confidence interval [CI] 89.2-90.4) in white, 89.8% (95%

195 mary endpoint) (adalimumab: TBR = 0.002, 95% confidence interval [CI] = -0.048 to 0.053; placebo: TBR

196 HBVr (adjusted hazard ratio [HR] = 5.14; 95% confidence interval [CI] = 1.77-14.92; P = .003).

197 e in event rates, 0.7 percentage points; 95% confidence interval [CI], -1.5 to 2.8; P=0.007 for nonin

198 eighted imaging-derived AAR (bias, 0.18; 95% confidence interval [CI], -1.6 to 1.3) and AAR derived f

199 deficits (26%) had worse 6MWD = -109 m (95% confidence interval [CI], -175 to -43), London Chest Act

200 ne group; between-group difference, 0.0; 95% confidence interval [CI], -2.0 to 2.1) or the Tiredness

201 p duration (1-year change in LVEF -3.6%; 95% confidence interval [CI], -4.4% to -2.8%; 3-year change

202 zure frequency, -22.8 percentage points; 95% confidence interval [CI], -41.1 to -5.4; P=0.01).

203 eight in the surgery group was -45.0 kg (95% confidence interval [CI], -47.2 to -42.9; mean percent c

204 was estimated to have ranged from 0.3% (95% confidence interval [CI], .1%-1.9%; 1 of 284 participant

205 either regimen (hazard ratio [HR], 0.43; 95% confidence interval [CI], .33-.57) and attainment of sus

206 D in Australia almost halved (IRR, 0.53; 95% confidence interval [CI], .50-.57), but differed by PCV

207 Comparative effectiveness was 24.0% (95% confidence interval [CI], .6%-42%); there was evidence o

208 ears (adjusted odds ratios [aOR] = 0.21; 95% confidence interval [CI], 0.05 to 0.97), 50-64 years (aO

209 o progression (relative risk [RR], 0.32; 95% confidence interval [CI], 0.06-1.85; I(2) = 0%) and of w

210 ean logMAR VA improvement of 0.17 units, 95% confidence interval [CI], 0.12-0.20, P < 0.01), whereas

211 and CVE rates in the cohort were 0.36% (95% confidence interval [CI], 0.31-0.42) and 0.12% (95% CI,

212 te of </=20/200 was 0.66/eye-year (EY), (95% confidence interval [CI], 0.32/EY to 1.22/EY); the rate

213 tients, the hazard ratio (HR) was 0.543 (95% confidence interval [CI], 0.321-0.918; P = .021), with m

214 n the control group (relative risk, 1.6; 95% confidence interval [CI], 0.4 to 6.8; absolute differenc

215 ander resuscitation (hazard ratio, 0.62; 95% confidence interval [CI], 0.47 to 0.82), as well as a lo

216 with sorafenib (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.57-0.77), being seen at a Na

217 s yielded areas under the curve of 0.72 (95% confidence interval [CI], 0.65 to 0.79) for the SPIROMIC

218 tients with PAD (hazard ratio [HR] 0.79; 95% confidence interval [CI], 0.66-0.94; P=0.0098) and witho

219 erator characteristic curve [AUC], 0.79; 95% confidence interval [CI], 0.74-0.83).

220 63 patients [11.3%]; hazard ratio, 0.85; 95% confidence interval [CI], 0.79 to 0.92; P<0.001) and the

221 n the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intent

222 al mortality (odds ratio, 1.04 per hour; 95% confidence interval [CI], 1.02 to 1.05; P<0.001), as was

223 7% in 2014 (prevalence ratio [PR], 1.05; 95% confidence interval [CI], 1.03-1.07).

224 azard ratio [HR], 1.10 per 10% increase; 95% confidence interval [CI], 1.04-1.16), low CSF to blood g

225 arization cumulative incidence was 2.3% (95% confidence interval [CI], 1.1-3.4), 3.5% (95% CI, 2.1-5.

226 tment (adjusted common odds ratio, 1.68; 95% confidence interval [CI], 1.15 to 2.45; P=0.007).

227 /=18 years of age (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.2-2.7), black race (OR, 1.5;

228 increase in age (odds ratio [OR], 1.44; 95% confidence interval [CI], 1.20-1.72; P < 0.01).

229 MUNO) subjects (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.22-1.37) and metabolically u

230 low (adjusted hazard ration [aHR], 1.55, 95% confidence interval [CI], 1.34-1.8) and medium (aHR, 1.2

231 t varenicline (relative risk [RR]: 2.64; 95% confidence interval [CI], 1.34-5.21) and bupropion (RR:

232 as 1.9 times as great as in noncarriers (95% confidence interval [CI], 1.4 to 2.7).

233 an fold rise from baseline [GMFR] = 1.6 [95% confidence interval [CI], 1.4,1.7], P value < .0001) and

234 es; standardized mean differences, 2.07; 95% confidence interval [CI], 1.44 to 2.69), but not minutes

235 loss of ZIKV RNA detection were 14 days (95% confidence interval [CI], 11 to 17) and 54 days (95% CI,

236 urveyed, there were 646 patients (11.9%; 95% confidence interval [CI], 11.1%-12.8%) with 727 distinct

237 Overall 2013-2014 incidence was 17.8 (95% confidence interval [CI], 16.6-19.2) cases per 100000 pe

238 rnal GBS colonization worldwide was 18% (95% confidence interval [CI], 17%-19%), with regional variat

239 neumocystis DNA was identified in 25.7% (95% confidence interval [CI], 17.8%-33.7%) of newborns studi

240 ly associated with systolic (4.58 mm Hg; 95% confidence interval [CI], 2.64-6.51) and diastolic (2.25

241 ted with increased risk of RD was 12.42 (95% confidence interval [CI], 2.91-53.01; P = 0.001) for eye

242 n overall incidence of 22.6 per 100 PYO (95% confidence interval [CI], 20.4-25.0).

243 acute erythema migrans ranged from 36% (95% confidence interval [CI], 25%-50%) to 54% (95% CI, 42%-6

244 djusted VE against A(H1N1)pdm09 was 43% (95% confidence interval [CI], 25%-57%).

245 inverse Simpson's alpha-diversity, 5.03; 95% confidence interval [CI], 4.08-6.14) than in the placebo

246 We estimated that 14.1% (95% confidence interval [CI], 6.3-21.9%) of HPV DNA detectio

247 5% during the index MI admission, 66.8% (95% confidence interval [CI], 65.9-67.8) had EF reassessment

248 ears of follow-up (implant: 11.9 points; 95% confidence interval [CI], 8.6-15.2; P < 0.001; systemic:

249 RNA with a diagnostic accuracy of 94.8% (95% confidence interval [CI], 89.4 to 97.6), a sensitivity o

250 and negative predictive value of 96.0% (95% confidence interval [CI], 90.2% to 98.9%), 65.9% (95% CI

251 age of agreement was excellent at 99.0% (95% confidence interval [CI], 98.6% to 99.2%; kappa, 0.89),

252 CA is rare (weighted prevalence = 0.03%; 95% confidence interval [CI]: 0.01% to 0.04%) compared with

253 (14.3% vs. 33.3%; odds ratio [OR]: 0.33, 95% confidence interval [CI]: 0.114-0.978).

254 e death and MI (hazard ratio [HR]: 0.65; 95% confidence interval [CI]: 0.50 to 0.84; p = 0.001), alth

255 core and all mortality predictors: 0.76; 95% confidence interval [CI]: 0.62 to 0.92; p = 0.005), wher

256 ecline in eGFR (hazard ratio [HR]: 0.77; 95% confidence interval [CI]: 0.66 to 0.89; p < 0.001), doub

257 andmark (year 1 hazard ratio [HR]: 0.82; 95% confidence interval [CI]: 0.67 to 0.99; year 2 HR: 0.90;

258 any and significant fibrosis were 0.92 (95% confidence interval [CI]: 0.86, 0.98) and 0.97 (95% CI:

259 ) for asthma ranging from 1.25 for PFOS (95% Confidence Interval [CI]: 0.90, 1.72) to 4.01 for PFDA (

260 the diagnosis of appendicitis was 0.97 (95% confidence interval [CI]: 0.95, 1.00) for PSV and 0.86 (

261 female subjects (odds ratio [OR]: 1.75, 95% confidence interval [CI]: 1.08-2.83, P-value<0.05).

262 se with high statin adherence were 1.50 (95% confidence interval [CI]: 1.30 to 1.73) for recurrent MI

263 (16%; ratio of averaged risk [RAR]: 3.2; 95% confidence interval [CI]: 1.5 to 7.5), LMWH and VKA (16%

264 ntitis was diagnosed at baseline (2.32%, 95% confidence interval [CI]: 1.50% to 3.15%), in patients s

265 sociations with heart failure (HR: 2.04; 95% confidence interval [CI]: 1.82 to 2.29), peripheral arte

266 General obesity (OR = 5.94, 95% confidence interval [CI]: 3.69-9.55) and central obesity

267 hypertension among US adults was 45.6% (95% confidence interval [CI]: 43.6% to 47.6%) and 31.9% (95%

268 1119 patients, pooled CTT was 58 hours (95% confidence interval [CI]: 50-65 hours).

269 age sensitivity and specificity was 68% (95% confidence interval [CI]: 59%, 76%) and 75% (95% CI: 71%

270 ive intervention (rate ratio [RR], 0.05 [95% confidence interval {CI}, .01-.38]).

271 mong children (relative risk [RR], 0.44 [95% confidence interval {CI}, .23-.85]; P = .014), and highe

272 sis was predictive of reduced SVR (0.51 [95% confidence interval {CI}, .31-.87]; P = .01).

273 eased significantly for SSTI (aOR, 0.85 [95% confidence interval {CI}, .76-.95]) and respiratory infe

274 osis (adjusted hazard ratio [aHR], 1.42 [95% confidence interval {CI}, .96-2.11]; aHR, 1.66 [95% CI,

275 ng etiology (overall weighted AF, 40.3% [95% confidence interval {CI}, 37.6%-44.3%]), though the AF w

276 eoperative experience (difference, 20.0; 95% confidence interval, CI, 16.6-23.3).

277 We estimated odds ratios (ORs) and 95% confidence intervals (CIs) by logistic regression with a

278 ecific mortality rate ratios (MRRs) with 95% confidence intervals (CIs) for all-cause and liver-relat

279 sed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for cancer-specific mortality

280 Hazard ratios (HRs) with 95% confidence intervals (CIs) for each outcome were extract

281 multivariate-adjusted hazard ratios and 95% confidence intervals (CIs) for FI risk in women receivin

282 We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for TBI in a Cox regression,

283 was used to estimate relative risks and 95% confidence intervals (CIs) from Cox proportional hazards

284 a statistically significant difference; 95% confidence intervals (CIs) were calculated.

285 estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs).

286 ts were estimated with hazard ratios and 95% confidence intervals computed in Cox regressions.

287 uivalence (ABE) acceptance criteria of a 90% confidence interval contained within the confidence limi

288 The 95% confidence interval for RMS diameters is 5.48 +/- 1.76 m

289 to 1.58; P=0.53); the upper limit of the 95% confidence interval for the difference in event rates fe

290 s (0.97 and 0.76 diopters, respectively; 90% confidence interval for treatment difference, -0.23 to 0

291 ma incidence, melanoma hazard ratios and 95% confidence intervals for lithium exposure were estimated

292 ronary atherosclerotic burden (increase [95% confidence interval] in rank of plaque volume for each 1

293 uoroscopic nephrostogram results, with a 95% confidence interval of 69.2% and 100%.

294 area with a loss less than first-percentile confidence interval of the variability in this group.

295 stimation provided prevalence ratios and 95% confidence intervals of ERG expression in relation to pa

296 the optimal motif length and calculating the confidence intervals of estimated parameters.

297 among protein coding genes: 23.5%-59.3% (95% confidence interval) of highly expressed genes with dist

298 ions were estimated by hazard ratios and 95% confidence intervals using Cox models adjusted for confo

299 as not significantly greater than 0, but the confidence interval was predominantly positive (M=0.019;

300 en had lower survival; hazard ratios and 95% confidence intervals were 1.63 (1.27-2.08), 1.38 (1.11-1

301 ntensive compared with the standard arm (95% confidence intervals) were 1.18 (0.40 to 3.33), 1.61 (0.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。